APEIRON Biologics closes oversubscribed financing round of EUR 17.5 million for the development of APN01 against COVID-19. Expansion of the ongoing phase II clinical trial to USA and Russia planned.

APEIRON Biologics AG has successfully completed a financing round totaling EUR 17.5 million, thus securing the further development of its drug candidate APN01 for the treatment of seriously ill COVID-19 patients and the further development of immuno-oncology projects. Expansion of the ongoing phase II clinical trial to USA and Russia planned.

Press release (EN) | Presseaussendung (DE)